• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Acorda Therapeutics Inc.

    6/10/22 4:24:36 PM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACOR alert in real time by email
    SC 13G 1 p22-1612sc13g.htm ACORDA THERAPEUTICS, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )*
     

    Acorda Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    00484M601

    (CUSIP Number)
     

    June 2, 2022

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 9 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 00484M601

    13GPage 2 of 9 Pages

     

    1

    NAMES OF REPORTING PERSONS

    SOROS FUND MANAGEMENT LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    - 0 -

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    - 0 -

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    - 0 -

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

    CUSIP No. 00484M601

    13GPage 3 of 9 Pages

     

    1

    NAMES OF REPORTING PERSONS

    GEORGE SOROS

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    - 0 -

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    - 0 -

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    - 0 -

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    CUSIP No. 00484M601

    13GPage 4 of 9 Pages

     

     

    Item 1(a). NAME OF ISSUER.
       
      The name of the issuer is Acorda Therapeutics, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 420 Saw Mill River Road, Ardsley, NY 10502.

     

    Item 2(a). NAME OF PERSON FILING:

     

      This statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"):

     

      (i)

    Soros Fund Management LLC ("SFM LLC"); and

     

      (ii) George Soros.

     

      This statement relates to shares of Common Stock (as defined herein) held for the accounts of Quantum Partners LP, a Cayman Islands exempted limited partnership ("Quantum Partners") and certain other funds/accounts (the "Other Funds/Accounts" and, together with Quantum Partners, the "Accounts"). SFM LLC serves as investment manager to the Accounts.  As such, SFM LLC has been granted investment discretion over portfolio investments, including the shares of Common Stock, held for the Accounts. George Soros serves as Chairman of SFM LLC and has sole discretion to replace FPR Manager LLC, the Manager of SFM LLC.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is 250 West 55th Street, 29th Floor, New York, NY 10019.

     

    Item 2(c). CITIZENSHIP:
       
      (i) SFM LLC is a Delaware limited liability company; and
         
      (ii) George Soros is a citizen of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Shares of common stock, par value $0.001 per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER:
       
      00484M601

     

     

    CUSIP No. 00484M601

    13GPage 5 of 9 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ¨ Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: _________________________

     

    Item 4. OWNERSHIP.
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
       
      On the date of the event which requires the filing of this Schedule 13G, each of the Reporting Persons may have been deemed to be the beneficial owner of more than five percent of the shares of Common Stock.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒

     

     

    CUSIP No. 00484M601

    13GPage 6 of 9 Pages

     

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      Not applicable..

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 00484M601

    13GPage 7 of 9 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: June 10, 2022

     

    SOROS FUND MANAGEMENT LLC  
         
    By: /s/ John DeSisto  
    Name: John DeSisto  
    Title: Assistant General Counsel  

     

     

    GEORGE SOROS  
         
    By: /s/ John DeSisto  
    Name: John DeSisto  
    Title: Attorney-in-Fact  

     

    CUSIP No. 00484M601

    13GPage 8 of 9 Pages

    EXHIBIT 1

    JOINT FILING AGREEMENT
    PURSUANT TO RULE 13d-1(k)

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

    DATE: June 10, 2022

     

    SOROS FUND MANAGEMENT LLC  
         
    By: /s/ John DeSisto  
    Name: John DeSisto  
    Title: Assistant General Counsel  

     

     

    GEORGE SOROS  
         
    By: /s/ John DeSisto  
    Name: John DeSisto  
    Title: Attorney-in-Fact  

     

     

    CUSIP No. 00484M601

    13GPage 9 of 9 Pages

     

    EXHIBIT 2

    POWER OF ATTORNEY

    KNOW ALL MEN BY THESE PRESENT, that I, GEORGE SOROS, hereby make, constitute and appoint each of JOHN DESISTO, NEAL DONNELLY, MICHAEL FLYNN, ANDREW HOLLENBECK, SARAH R. MOROS and JOSEPH WORKMAN, acting individually, as my agent and attorney-in-fact for the purpose of executing in my name, (a) in my personal capacity or (b) in my capacity as Chairman of, member of or in other capacities with Soros Fund Management LLC ("SFM LLC") and each of its affiliates or entities advised by me or SFM LLC, all documents, certificates, instruments, statements, filings and agreements ("documents") to be filed with or delivered to any foreign or domestic governmental or regulatory body or required or requested by any other person or entity pursuant to any legal or regulatory requirement relating to the acquisition, ownership, management or disposition of securities, futures contracts or other investments, and any other documents relating or ancillary thereto, including without limitation all documents relating to filings with the Commodities Futures Trading Commission and National Futures Association, the United States Securities and Exchange Commission (the "SEC") pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934 (the "Act") and the rules and regulations promulgated thereunder, including all documents relating to the beneficial ownership of securities required to be filed with the SEC pursuant to Section 13(d) or Section 16(a) of the Act and any information statements on Form 13F required to be filed with the SEC pursuant to Section 13(f) of the Act.

    All past acts of these attorneys-in-fact in furtherance of the foregoing are hereby ratified and confirmed.

    Execution of this power of attorney revokes that certain Power of Attorney dated as of the 20th day of August, 2021 with respect to the same matters addressed above.

    This power of attorney shall be valid from the date hereof until revoked by me.

    IN WITNESS WHEREOF, I have executed this instrument as of the 1st day of February, 2022.

     

    GEORGE SOROS  
         
    By: /s/ Maryann Canfield  
    Name: Maryann Canfield  
    Title: Attorney-in-Fact for George Soros  

     

    Get the next $ACOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACOR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ACOR
    Leadership Updates

    Live Leadership Updates

    See more
    • Acorda Therapeutics Announces Resignation of Chief Operating Officer

      Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Lauren Sabella, Chief Operating Officer, will resign from the Company effective September 30, 2022. Ms. Sabella will be working in a strategic advisory role for early-stage biotechnology companies. "We are grateful for Lauren's thirteen years of contributions as a member of Acorda's executive leadership team. Initially, she and her team led the commercial launch of AMPYRA, a novel treatment for multiple sclerosis. The tremendous success of that product allowed Acorda to invest in additional clinical development programs, including INBRIJA for Parkinson's disease," said Ron Cohen, M.D., Acorda's President and CEO. "Lauren has been

      8/19/22 8:00:00 AM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACOR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Acorda Therapeutics Inc.

      10-Q - Acorda Therapeutics, Inc. (0001008848) (Filer)

      5/14/24 8:24:14 AM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K/A filed by Acorda Therapeutics Inc. (Amendment)

      10-K/A - Acorda Therapeutics, Inc. (0001008848) (Filer)

      4/29/24 8:39:11 AM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Acorda Therapeutics, Inc. (0001008848) (Filer)

      4/25/24 8:00:48 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Acorda Therapeutics Announces Delisting from Nasdaq

      Acorda Therapeutics, Inc. today announced that its common stock is no longer listed on the Nasdaq Stock Market. The delisting is a result of the Company's failure to demonstrate compliance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1 as a result of the Company's commencement of Chapter 11 proceedings and Nasdaq Listing Rule 5450(b)(1)(A) for failure to maintain stockholders' equity of at least $10 million. Trading in the Company's common stock on the Nasdaq exchange was suspended on April 12, 2024. The Company's common stock is quoted on the OTC Pink® Open Market platform operated by OTC Markets Group Inc. since April 12, 2024 under the "ACORQ" ticker symbol. About Acorda Therap

      4/15/24 5:03:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Therapeutics Announces Nasdaq Delisting Notification

      Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced that Nasdaq Stock Market ("Nasdaq") today notified the Company that it will suspend trading in and delist the Company's common stock, effective with the opening of business on April 12, 2024. The notice follows the Company's April 1, 2024 announcement that it has reached an agreement with Merz Therapeutics to acquire substantially all of the assets of the Company. In connection with that announcement, Acorda and certain of its affiliates filed voluntary petitions to commence Chapter 11 proceedings in the U.S. Bankruptcy Court for the Southern District of New York. Nasdaq commenced proceedings to delist the Company's common stock, based on th

      4/3/24 5:30:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Therapeutics and Merz Announce Signing of "Stalking Horse" Asset Purchase Agreement

      Acorda Files for Voluntary Chapter 11 Protection to Facilitate Orderly Sale Acorda Enters into a Restructuring Support Agreement with over 90% of the Secured Convertible Noteholders Patient Access to INBRIJA® (levodopa inhalation powder) and AMPYRA® (dalfampridine) to Continue Uninterrupted Acorda Therapeutics, Inc. (NASDAQ:ACOR) ("Acorda" or "the Company") today announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to INBRIJA, AMPYRA, and FAMPYRA for $185 million. Merz Therapeutics, a leader in the field of neurotoxins, is a business of the global family-owned company Merz, hea

      4/1/24 6:35:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACOR
    Financials

    Live finance-specific insights

    See more
    • Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024

      Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it will no longer hold its fourth quarter and year end 2023 earnings conference call originally scheduled for Monday, April 1 at 4:30 p.m. ET. The Company does expect to timely file its Annual Report on Form 10-K for the period ended December 31, 2023. About Acorda Therapeutics Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® is approved for intermittent treatment of OFF episodes in adults with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor

      4/1/24 4:01:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024

      Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced a webcast/conference call in conjunction with its fourth quarter and year end 2023 update and financial results for Monday, April 1 at 4:30 p.m. ET. To participate in the webcast, please use the following registration link: https://events.q4inc.com/attendee/373031481 If you register for the webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation email with the webcast details. On the day of the webcast, you will receive an email 2 hours prior to the start of the webcast with the link to join. The presentation will be

      3/25/24 4:01:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Therapeutics Reports Third Quarter 2023 Financial Results

      INBRIJA® (levodopa inhalation powder) Q3 2023 U.S. net revenue of $8.1 million; 4% increase over Q3 2022 AMPYRA® (dalfampridine) Q3 2023 net revenue of $15.7 million; 26% decrease over Q3 2022 INBRIJA ex-U.S. revenue of $1.4 million; FAMPYRA royalties of $2.5 million Biopas Laboratories files for approval of INBRIJA in six Latin American countries Acorda Therapeutics, Inc. (NASDAQ:ACOR) today provided a business update and reported its financial results for the third quarter ended September 30, 2023. "We were pleased to see a 32% increase in new INBRIJA prescription requests in Q3 2023 over Q3 2022. New prescription requests have increased by 38% in the first three quarters o

      11/13/23 4:01:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ACOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ACOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 4 filed by Burns Thomas M.

      4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      6/23/23 7:59:21 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Burns Thomas M.

      3 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      6/23/23 7:57:11 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Varian John

      4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      6/23/23 5:38:37 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Acorda Therapeutics Inc. (Amendment)

      SC 13D/A - Acorda Therapeutics, Inc. (0001008848) (Subject)

      5/10/23 4:37:39 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Acorda Therapeutics Inc. (Amendment)

      SC 13D/A - ACORDA THERAPEUTICS INC (0001008848) (Subject)

      3/10/23 4:15:17 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Acorda Therapeutics Inc. (Amendment)

      SC 13G/A - ACORDA THERAPEUTICS INC (0001008848) (Subject)

      2/14/23 4:52:06 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Therapeutics upgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. upgraded Acorda Therapeutics from Neutral to Buy and set a new price target of $10.00 from $5.00 previously

      6/17/21 6:09:07 AM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care